Injection Site Reactions with Biologic Medications

Incidence and Severity

The British Journal of Dermatology reports that injection site reactions with biologic medications occur in 14-37% of patients, depending on the specific agent, and are generally mild to moderate in severity, rarely leading to treatment discontinuation 1, 2, 3, 4
The frequency of injection site reactions differs substantially across biologic therapies, with etanercept having the highest rates of 37% observed in placebo-controlled rheumatologic trials 1, 2, 3
Adalimumab is associated with a 15% incidence of injection site reactions, compared to 9% with placebo or active control 1, 2, 3
Ustekinumab has an uncommon incidence of injection site reactions at 1.5%, likely due to infrequent dosing 5
In children with psoriasis treated with biologics, primarily etanercept and adalimumab, injection site reactions occurred in 18.9% of patients in retrospective analysis 6

The majority of injection site reactions are mild to moderate, manifesting as erythema, itching, pain, swelling, bleeding, or bruising at the injection site, and do not require treatment discontinuation 1, 2, 3
Most reactions occur during the first month of treatment and subsequently decrease in frequency 1, 2, 3
Reactions generally do not necessitate drug discontinuation, and the British Journal of Dermatology recommends reassurance that reactions typically diminish with ongoing therapy 1, 2, 3
Symptomatic treatment with topical measures may be considered for persistent or bothersome reactions 3
The British Journal of Dermatology suggests continuing therapy unless a severe allergic reaction occurs 3